Rappaport Family Institute for Research in the Medical Sciences

Oncohost Ltd.

Technion Research & Development Foundation Ltd

Yuval Shaked

Ella Fremder

Eyal Jacob

Ami Aronheim

Ziv Raviv

Dror Yeger

A method is provided for treating a cancer patient non-responsive to treatment with a cancer therapy by treating the patient with said cancer therapy in combination with an agent that blocks the activity of a dominant factor selected among the plurality of host-driven resistance factors generated in response to treatment of the cancer patient with the cancer therapy, these factors having a fold-change predictive of a non-favorable response of the cancer patient to the treatment with the cancer therapy.

Method of treating cancer with a cancer therapy in combination with another therapeutic agent

A method is provided for treating a cancer patient non-responsive to treatment with a immune checkpoint inhibitor (ICI) by treating the patient with said ICI in combination with an agent that blocks the activity of a dominant factor selected among the plurality of host-driven resistance factors generated in response to treatment of the cancer patient with the ICI, these factors having a fold-change predictive of a non-favorable response of the cancer patient to the treatment with the ICI.

Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent

A method and a kit are provided for predicting a favorable or a non-favorable response of a cancer patient to treatment with an immune checkpoint inhibitor by determining in a biological sample obtained from the cancer patient, before and after the treatment, the changes of the levels of factors/biomarkers generated by the cancer patient in response to said treatment, and a method for treatment of a cancer patient with an immune checkpoint inhibitor.

Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors, method of treating cancer, and kit therefor

Provided are blocking agents to IL-1α, IL-1β, or IL-1R activity for use in combination with radiotherapy for treating cancer patients in which radiotherapy treatment induces IL-1α, IL-1β or both in their circulation.

Cancer treatment by blocking host-induced IL-1 in combination with radiotherapy

Provided are blocking agents to IL-1&#x3b1;, IL-1&#x3b2;, or IL-1R activity for use in combination with radiotherapy for treating cancer patients in which radiotherapy treatment induces IL-1&#x3b1;, IL-1&#x3b2; or both in their circulation.

A method for treating cancer and/or preventing or reducing metastasis or treating angiogenesis related disorders comprising the step of administering IL-31 or peptide which is at least about 70%, homologous to the IL-31 sequence as set forth in SEQ ID No. 1.

Growing community of inventors

Binyamina, Israel

Yuval Shaked